Description: Amikacin is a semisynthetic derivative of kanamycin with similar pharmacokinetic properties and dosages. It is resistant to many of the bacterial R factor-mediated enzymes that inactivate kanamycin and gentamicin. Noteworthy is its effect against Pseudomonas aeruginosa and against most Gram-negative aerobes that are resistant to gentamicin and tobramycin. There are strains of Staphylococcus aureus that inactivate amikacin by phosphorylation and adenylation.
Amikacin is a semi-synthetic derivative of kanamycin. It is much less sensitive to the enzymes that inactivate aminoglycoside antibiotics. The spectrum is similar to that of gentamicin. Amikacin principally finds use in the treatment of infections arising from bacteria that are resistant to gentamicin and/or tobramycin.